| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.017 | 0.8 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.0091 | 0.8 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | selumetinib:UNC0638 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.8 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |